We noted a strong synergy of anthracyclines with Setanaxib for decreasing viability of FLT3-ITD-positive AML cells in vitro, and also therapeutic activity of Setanaxib in a mouse model of FLT3-ITD driven myeloproliferation. Here, FLT3 is linked to acute myeloid leukemia.